Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02008877 | SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | completed | Phase 1 / Phase 2 | 20 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01313936 | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | completed | Phase 1 | 32 | University of California, San FranciscoOTHER | 1 | Apr 29, 2019 |
| clinicaltrials |
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM(HERT-GBM) | completed | Phase 1 | 16 | Baylor College of MedicineOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT01688401 | Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). | completed | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT01644773 | Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) | completed | Phase 1 | 36 | St. Jude Children's Research HospitalOTHER | 1 | Mar 22, 2019 | clinicaltrials |
| NCT03101579 | Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer | completed | Phase 1 | 13 | The First Hospital of Jilin UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02189109 | The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma(GBM) | completed | Phase 1 | 11 | NuvOx LLCINDUSTRY | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00977431 | Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform | completed | Phase 1 | 36 | Boehringer IngelheimINDUSTRY | 1 | Feb 18, 2019 | clinicaltrials |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01576692 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 1 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02853565 | A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 10 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT02728349 | Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma | completed | Phase 1 | 26 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., LtdINDUSTRY | 1 | Nov 1, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02718443 | VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | completed | Phase 1 | 14 | Vaximm GmbHINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02253212 | Safety of BBB Opening With the SonoCloud(SONOCLOUD) | completed | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01967758 | Phase I Study of Safety and Immunogenicity of ADU-623 | completed | Phase 1 | 11 | Providence Health & ServicesOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02049489 | A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma | completed | Phase 1 | 20 | Precision Life Sciences GroupINDUSTRY | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02149225 | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients | completed | Phase 1 | 16 | Immatics Biotechnologies GmbHINDUSTRY | 5 | Aug 7, 2018 | clinicaltrials |
| NCT01151670 | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01462396 | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors(STALLO) | completed | Phase 1 | 4 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00805376 | DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas | completed | Phase 1 | 37 | DNAtrix, Inc.INDUSTRY | 1 | Jul 16, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01644955 | Carboplatin in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 10 | James ElderOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT01156584 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | completed | Phase 1 | 54 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01470794 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | completed | Phase 1 | 58 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | completed | Phase 1 | 17 | Tocagen Inc.INDUSTRY | 1 | May 21, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00766753 | Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 22 | Frank LiebermanOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00693095 | Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer(ERaDICATe) | completed | Phase 1 | 23 | John SampsonOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT02130869 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | completed | Phase 1 | 8 | St. Jude Children's Research HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01171469 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | completed | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01800695 | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme | completed | Phase 1 | 202 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01172964 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT01956734 | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma(D24GBM) | completed | Phase 1 | 31 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00946673 | Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Stanford UniversityOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | completed | Phase 1 | 50 | St. Jude Children's Research HospitalOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01975116 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | completed | Phase 1 | 18 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 7, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma | completed | Phase 1 | 18 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01132911 | A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas | completed | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2019source: clinicaltrials